Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Baird said Regeneron represents an opportunity with a significant downstream upside. The firm cited the company’s announcement it will begin Phase lll development of REGN727 next month but the FDA guidance is that cardiovascular outcomes will not be a prerequisite for approval. Shares are Outperform rated with a $150 price target. Baird lowered its price target on Research in Motion following its expectations of Q1 losses due to continued competition. The firm also believes a potential buyer of the company is a longshot. shares are Underperform rated.
Roadrunner Transportation Syste (NYSE:RRTS): Baird said Roadrunner remains a best idea and they remain buyers at current levels following its announcement of two new LTL terminals. The firm believes its network expansion will lead to volume growth and share gain potential. Shares are Outperform rated with a $23 price target.
Par Pharmaceutical Companies Inc. (NYSE:PRX): After a Delaware court upheld the validity of a patent for Lovaza – a fish oil product that Par hopes to produce a generic version of – ThinkEquity lowered its target on Par to $47 from $50. The firm, however, still believes that Par can win an appeal and produce a generic version of the drug by 2014, and it maintains a Buy rating on Par.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.